FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034209904> ?p ?o ?g. }

• W2034209904 endingPage "378" @default.
• W2034209904 startingPage "377" @default.
• W2034209904 abstract "Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor).The phase Ib study followed a 3 + 3 dose-escalation design with three dose levels. The primary objective in the follow-on phase II study was improvement in 2-month progression-free survival (PFS) from 30% (historical benchmark) to 50% in patients with refractory, metastatic colorectal cancer.Dose-limiting toxicities in the phase Ib study were grade 3 fatigue and dehydration. Oral tivozanib (1 mg daily for 3 of 4 weeks) and oral everolimus (10 mg daily continuously) were advanced to a 40-patient phase II study. The most common grade 3-4 adverse events were thrombocytopenia and hypophosphatemia. The 2-month PFS rate was 50%, with 20 of 40 patients having stable disease (SD). Seven (18%) patients were treated for ≥6 months. Median PFS and overall survival (OS) times were 3.0 months (95% confidence interval [CI]: 1.9-3.6 months) and 5.6 months (95% CI: 4.4-10.6 months), respectively. Patients who developed grade 1+ hypertension had increased SD rates (65.2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months).The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer." @default.
• W2034209904 created "2016-06-24" @default.
• W2034209904 creator A5002261325 @default.
• W2034209904 creator A5007257334 @default.
• W2034209904 creator A5008468404 @default.
• W2034209904 creator A5027170448 @default.
• W2034209904 creator A5030262534 @default.
• W2034209904 creator A5042529049 @default.
• W2034209904 creator A5045494904 @default.
• W2034209904 creator A5047496278 @default.
• W2034209904 creator A5049314303 @default.
• W2034209904 creator A5053848207 @default.
• W2034209904 creator A5072727753 @default.
• W2034209904 creator A5075625649 @default.
• W2034209904 creator A5077382664 @default.
• W2034209904 creator A5081543892 @default.
• W2034209904 creator A5081890512 @default.
• W2034209904 creator A5088566246 @default.
• W2034209904 creator A5088893766 @default.
• W2034209904 creator A5089509810 @default.
• W2034209904 creator A5090604653 @default.
• W2034209904 date "2013-04-01" @default.
• W2034209904 modified "2023-10-16" @default.
• W2034209904 title "Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer" @default.
• W2034209904 doi "https://doi.org/10.1634/theoncologist.2012-0378" @default.
• W2034209904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3639523" @default.
• W2034209904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23580238" @default.
• W2034209904 hasPublicationYear "2013" @default.
• W2034209904 type Work @default.
• W2034209904 sameAs 2034209904 @default.
• W2034209904 citedByCount "38" @default.
• W2034209904 countsByYear W20342099042013 @default.
• W2034209904 countsByYear W20342099042014 @default.
• W2034209904 countsByYear W20342099042015 @default.
• W2034209904 countsByYear W20342099042016 @default.
• W2034209904 countsByYear W20342099042017 @default.
• W2034209904 countsByYear W20342099042018 @default.
• W2034209904 countsByYear W20342099042019 @default.
• W2034209904 countsByYear W20342099042020 @default.
• W2034209904 countsByYear W20342099042021 @default.
• W2034209904 countsByYear W20342099042022 @default.
• W2034209904 crossrefType "journal-article" @default.
• W2034209904 hasAuthorship W2034209904A5002261325 @default.
• W2034209904 hasAuthorship W2034209904A5007257334 @default.
• W2034209904 hasAuthorship W2034209904A5008468404 @default.
• W2034209904 hasAuthorship W2034209904A5027170448 @default.
• W2034209904 hasAuthorship W2034209904A5030262534 @default.
• W2034209904 hasAuthorship W2034209904A5042529049 @default.
• W2034209904 hasAuthorship W2034209904A5045494904 @default.
• W2034209904 hasAuthorship W2034209904A5047496278 @default.
• W2034209904 hasAuthorship W2034209904A5049314303 @default.
• W2034209904 hasAuthorship W2034209904A5053848207 @default.
• W2034209904 hasAuthorship W2034209904A5072727753 @default.
• W2034209904 hasAuthorship W2034209904A5075625649 @default.
• W2034209904 hasAuthorship W2034209904A5077382664 @default.
• W2034209904 hasAuthorship W2034209904A5081543892 @default.
• W2034209904 hasAuthorship W2034209904A5081890512 @default.
• W2034209904 hasAuthorship W2034209904A5088566246 @default.
• W2034209904 hasAuthorship W2034209904A5088893766 @default.
• W2034209904 hasAuthorship W2034209904A5089509810 @default.
• W2034209904 hasAuthorship W2034209904A5090604653 @default.
• W2034209904 hasBestOaLocation W20342099041 @default.
• W2034209904 hasConcept C121332964 @default.
• W2034209904 hasConcept C121608353 @default.
• W2034209904 hasConcept C126322002 @default.
• W2034209904 hasConcept C126894567 @default.
• W2034209904 hasConcept C142424586 @default.
• W2034209904 hasConcept C143998085 @default.
• W2034209904 hasConcept C197934379 @default.
• W2034209904 hasConcept C2778375690 @default.
• W2034209904 hasConcept C2779699572 @default.
• W2034209904 hasConcept C31760486 @default.
• W2034209904 hasConcept C526805850 @default.
• W2034209904 hasConcept C535046627 @default.
• W2034209904 hasConcept C71924100 @default.
• W2034209904 hasConcept C87355193 @default.
• W2034209904 hasConcept C90924648 @default.
• W2034209904 hasConceptScore W2034209904C121332964 @default.
• W2034209904 hasConceptScore W2034209904C121608353 @default.
• W2034209904 hasConceptScore W2034209904C126322002 @default.
• W2034209904 hasConceptScore W2034209904C126894567 @default.
• W2034209904 hasConceptScore W2034209904C142424586 @default.
• W2034209904 hasConceptScore W2034209904C143998085 @default.
• W2034209904 hasConceptScore W2034209904C197934379 @default.
• W2034209904 hasConceptScore W2034209904C2778375690 @default.
• W2034209904 hasConceptScore W2034209904C2779699572 @default.
• W2034209904 hasConceptScore W2034209904C31760486 @default.
• W2034209904 hasConceptScore W2034209904C526805850 @default.
• W2034209904 hasConceptScore W2034209904C535046627 @default.
• W2034209904 hasConceptScore W2034209904C71924100 @default.
• W2034209904 hasConceptScore W2034209904C87355193 @default.
• W2034209904 hasConceptScore W2034209904C90924648 @default.
• W2034209904 hasIssue "4" @default.
• W2034209904 hasLocation W20342099041 @default.
• W2034209904 hasLocation W20342099042 @default.
• W2034209904 hasLocation W20342099043 @default.
• W2034209904 hasLocation W20342099044 @default.
• W2034209904 hasOpenAccess W2034209904 @default.

• next